News

Novartis Pharma AG: Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients ...
Taiwan News1h
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...
EuropaWire14h
Novartis Phase III Trials Show Ianalumab Significantly Improves Outcomes in Sjögren’s Disease
Novartis has reported landmark Phase III results showing that ianalumab significantly reduced disease activity in patients with Sjögren’s dise ...
Medindia22h
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren's disease. Both trials met the primary endpoint of ...
Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy’ Stocks
Detailed price information for Wave Life Sci Ord Sh (WVE-Q) from The Globe and Mail including charting and trades.